-1.16% to Target, Bernstein Sticks With ‘Market Perform’ Rating on AstraZeneca (LON:AZN) Shares Today


AstraZeneca (LON:AZN) Rating Reaffirmed

Recently, In an analyst note published on Friday, 18 December, AstraZeneca (LON:AZN) shares have had their Market Perform Rating reiterated by investment analysts at Bernstein, who currently has a GBX 4346 price target on company. This target by Bernstein indicates the possibile downside of -1.16% from the current price.

From a total of 28 analysts covering AstraZeneca PLC (LON:AZN) stock, 0 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that NaN of the ratings are positive. The highest target price is GBX 94.49 while the lowest target price is GBX 36. The mean of all analyst targets is GBX 70.52 with a 9.89% above today’s (GBX 4390) stock price. AstraZeneca PLC was the topic of 125 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. JP Morgan maintained shares on December 18 with “Neutral” rating. Jefferies maintained shares with “Buy” rating and GBX 5300 target share price in a report from a December 7. Barclays Capital maintained AZN stock in a recent report from December 16 with “Underweight” rating. Handelsbanken maintained the rating on December 4. Handelsbanken has a “Accumulate” rating and a GBX 4959.33 price target on shares. Finally, BNP Paribas maintained the stock with “Outperform” rating in a report issued on a December 9.

Approximately 1.21 million shares of stock traded hands. AstraZeneca plc (LON:AZN) has risen 0.20% since May 21, 2015 and is uptrending. It has outperformed by 4.01% the S&P500.

-1.16% to Target, Bernstein Sticks With ‘Market Perform’ Rating on AstraZeneca (LON:AZN) Shares Today

AstraZeneca PLC is a global biopharmaceutical company. The company has a market cap of 54.55 billion GBP. The Firm discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. It has 49.13 P/E ratio. The Company’s medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”